We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A total of 40.3% of patients treated with dupilumab ...
“Atopic hand and foot dermatitis can extensively disrupt the lives of patients, given the intense itch and painful skin lesions it causes on essential body areas. In this trial, Dupixent significantly ...
“Living with atopic dermatitis on your most essential body areas like the hands and feet can make daily activities including walking and writing incredibly burdensome even in the case where disease ...
Dupilumab improved the signs and symptoms and quality of life in adults and adolescents with moderate to severe atopic hand and foot dermatitis compared with placebo. The results of the study "support ...
Findings showed 40% of patients treated with dupilumab achieved an IGA score of 0 (clear) or 1 (almost clear) on the hands and feet at week 16, compared with 17% of those who received placebo. The ...
Please provide your email address to receive an email when new articles are posted on . The updated label shows safety and efficacy in treating moderate to severe atopic dermatitis of the hands or ...
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of ...
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results